Caris AI Study Links Treatment Selection to Longer Survival in Pancreatic Cancer

01 Utilize AI-guided treatment selection to enhance survival rates in pancreatic cancer patients.

02 Identify patients likely to benefit from FOLFIRINOX over gemcitabine plus nab-paclitaxel with molecular data.

03 Achieve a median overall survival of 16.0 months with FOLFIRINOX versus 9.9 months with gem/nab-p.

04 Leverage insights from Caris study to improve personalized treatment strategies for advanced pancreatic cancer.

The full story Caris AI Study Links Treatment Selection to Longer Survival in Pancreatic Cancer Read the story